Publications

Gilligan T, Bohlke K, Alpert AB, Coyle N, Harichand-Herdt S, Lathan CS, Razis E, Rivera K, Sanft T, Seigel C, Times M, Chou CL. Patient-Clinician Communication: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41805420

Datta D, Nzau M. Targeted therapy for ALK-positive histiocytosis masquerading as optic nerve tumor: a case report. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2026. PMID: 41803275

Vijayaraghavan M, Williams A, Bonniot C, Cheng C, Clark B, Safier J, Satterfield J, Pamatmat M, Schroeder SA. State Leadership Academies to Reduce Tobacco Use Prevalence in the United States: Four Case Studies of Early State Adopters of Tobacco Treatment and Policy. Public health reports (Washington, D.C. : 1974). 2026. PMID: 41797633

Al-Toma D, Kemna R, Ali M, Zwart K, Zeeuw MJ, Stehouwer BL, de Jong PA, Kurk S, Braat MNGJA, Lagendijk JJW, May AM, Koopman M, Verpalen IM, Swijnenburg RJ, Punt CJA, Kazemier G, Bol GM. Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial. European journal of cancer (Oxford, England : 1990). 2026. PMID: 41819026

Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A, Blanco A, Chari A, Martin T, Wolf J, Rey-Bua B, Mateos MV, Kortüm KM, Riedhammer C, Tamariz-Amador LE, Valencia E, Rodríguez-Otero P, San Miguel J, Ibarra G, Oriol A, Cedena MT, López-Muñoz N, Alonso R, Calbacho M, Sanchez-Pina JM, Linares M, Martínez-López J. Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. Journal for immunotherapy of cancer. 2026. PMID: 41791791

Nadine Goldhammer, Marin Bont, Shruti Warhadpande, Michael Choi, Jose Cedano, Heather Greenwood, Julia Ye, Christopher Schwartz, Michael Alvarado, Cheryl Ewing, Karen Goodwin, Rita Mukhtar, Jasmine Wong, Shoko Abe, Julia Chandler, Jordan Jackson, Olufunmilayo Olopade, Michael Campbell, Allison Lam, Chaelee Park, Anna Vertido, Laura van 't Veer, Nola Hylton, Laura Esserman, Jennifer Rosenbluth. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue bioRxiv. 2026. PMID:

Jhaveri K, Bidard FC, Kalinsky K, Neven P, Rugo HS, Tolaney SM, Litchfield LM, von Laue CC, Traore S, Sapunar F, Li Y, O'Shaughnessy J. Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials. ESMO open. 2026. PMID: 41785668

Kim J, Munster PN. Cracks in the Estrogen Carcinogenesis of Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41785447

Slovin S, Gao X, Wei XX, Oh DY, McKay RR, Falchook G, Hussain A, McKean M, Wibmer A, Ho A, Eskew JD, Belani R, Coronella J, Haag S, Martin CE, McCaigue J, Mendoza J, Murphy A, Namini H, Spear MA, Shedlock DJ, Dorff TB. Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC). Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41779004

Bivona TG, Yanai I, Calabrò F, Mechta-Grigoriou F, Corleone G, Di Martile M, Tocci A, Tocci P, Vaccarella S, Ferriero MC, Alimonti A, Ruppin E, Nisticò P, Bagnato A, Blandino G. Challenges and advances in drug resistance and tolerance in cancer. Journal of experimental & clinical cancer research : CR. 2026. PMID: 41776655

Goldhammer N, Bont M, Warhadpande S, Choi M, Cedano J, Greenwood H, Ye J, Schwartz CJ, Alvarado M, Ewing C, Goodwin K, Mukhtar RA, Wong J, Abe SE, Chandler J, Jackson J, Olopade OI, Campbell MJ, Lam A, Park C, Vertido A, van 't Veer LJ, Hylton N, Esserman LJ, Rosenbluth JM. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue. bioRxiv : the preprint server for biology. 2026. PMID: 41867809

Chrostek MR, Robinson J, Krishnan R, Yu EY, Nordquist LT, Vandross AL, Salkeni MA, Schehr J, Mannino M, Hintz A, Caceres J, Vatani M, Emamekhoo H, Nelson P, Markey C, Coates E, Breitmeyer J, Fong L, De Bono JS, Lang JM, Zhao SG. Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534. Investigational new drugs. 2026. PMID: 41774321

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N, Saji S, Miyoshi Y, Bardia A, Harbeck N, Haiderali A, Fan L, Mejia JA, Karantza V, Llombart-Cussac A. KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41405563

Wan J, Saatcioglu HD, Ellis H, Aguado-Fraile E, Xu Q, Kondo H, Manguso RT, Gritti I, Norden BL, Noble C, Corcoran RB, Lubner SJ, Javle M, Abou-Alfa GK, Cleary JM, Kelley RK, Borad MJ, Macarulla T, Oh DY, Daigle S, Gliser C, Pandya S, Choe S, Tron AE, Bardeesy N. MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41460204

Hammer MJ, Harris C, Pozzar R, Snowberg K, Paul SM, Cooper BA, Abbott ME, Chang S, Kenfield S, Van Blarigan E, Van Loon K, Levine JD, Miaskowski C. Symptom Clusters and Symptom Burden in Cancer Survivors. Cancer medicine. 2026. PMID: 41787680

Chan SL, Yau T, Kelley RK, Finn RS, Yoo C, Furuse J, Ren Z, Klümpen HJ, Ozaka M, Pelzer U, Arslan C, Park JO, Edeline J, Valle JW, Ueno M, Vogel A, Starkopf L, Malhotra U, Siegel AB, Qin S. Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study. Cancer Research Communications. 2026. PMID: 41757470

Leonhardt CS, Adham M, Bazarbashi S, Ben-Aharon I, Beets-Tan RGH, Boggi U, Brunner TB, Cellini F, Chiti A, Daamen L, De Bari B, De Dosso S, Ducreux M, Eng C, Falconi M, Ferrone CR, Frigerio I, Garajova I, Gerum S, Ghadimi M, Gruenberger T, Hammel P, Haustermans K, Hawkins M, He J, Heerkens HD, Huguet F, Intven MPW, Klaiber U, Kroese TE, Laurent-Puig P, Lordick F, Ludmir EB, Macarulla T, Matzinger O, Morganti AG, Mukherjee S, O'Reilly EM, Park JO, Papamichael D, Pfeiffer P, Ramia JM, Roeder F, Ruiz-García E, Satoi S, Scorsetti M, Schneider M, Seufferlein T, Serrablo A, Shrikhande SV, Smyth EC, Svrcek M, Takaori K, Tempero MA, Tissera NS, Tie J, Torres OJM, Turpin A, Van Cutsem E, Versteijne E, Vivaldi C, Wainberg ZA, Weichselbaum RR, Weitz J, Wolfgang CL, Prager GW, Strobel O. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. The Lancet. Oncology. 2026. PMID: 41785904

L'Espérance K, Lin K, Lichtensztajn D, Christoph Soerensen SJ, Gulati S, Deng Z, Leppert JT, Oh DY, Sakoda LC, Washington SL, Meng MV, Chan JM, Langston ME, Cheng I, Chung BI, Graff RE. Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019. Lancet regional health. Americas. 2026. PMID: 41800233

Correia N, Johnson K, Durr M, Grimes BA, Lazar AA, Sarkar U, Ha PK, Chen L, Wai KC, Likhterov I, Yom SS, Chan JW, Algazi AP, Kang H, Ryan WR, Heaton CM, El-Sayed I, George J, Xu MJ. Timely Matters: Predictors of Delay in Oral Cavity Cancer Patients Across the Care Continuum. Laryngoscope investigative otolaryngology. 2026. PMID: 41767548

Armstrong AJ, Morris MJ, Abida W, Aggarwal RR, Antonarakis ES, Attard G, Beltran H, Bryce A, Carducci MA, Cheng HH, Chen DL, Chi KN, Childs DS, Dahut W, Emmett L, Fizazi K, Gafita A, George DJ, Hermann K, Hofman MS, Hope T, Hussain M, Kelly WK, Kessler E, Kuo PH, Lang J, Liu G, Marshall CH, Morgans AK, McKay RR, Nanus D, Nelson P, Paller C, Reichert ZR, Ryan CJ, Sartor AO, Schöder H, Schwartz LH, Sharifi N, Stadler WM, Stein M, Sternberg CN, Szmulewitz RZ, Tagawa ST, Sokolova AO, Wyatt AW, Yamoah K, Yu EY, Halabi S, Scher HI, PCWG4 Writing Group. Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41744290